Key result
Tacrolimus-based immunosuppression significantly improved health-related quality of life on the Bergner Physical Appearance scale compared to cyclosporine (P<0.05).
Why the study?
Does tacrolimus-based immunosuppression improve health-related quality of life compared to cyclosporine-based immunosuppression in kidney transplant patients?
Population
303 kidney transplant patients participating in a multicenter, prospective, randomized, phase III trial
Comparison
Tacrolimus-based immunosuppression vs Cyclosporine-based immunosuppression
Design
RCT, randomized
Follow-up
12 months
Authors
Loading...
Tacrolimus improves physical appearance quality of life versus cyclosporine after kidney transplant; extends RCT comparisons to domain-specific HRQoL benefits.
RCT (n=303)
randomized
Yes
Does tacrolimus-based immunosuppression improve health-related quality of life compared to cyclosporine-based immunosuppression in kidney transplant patients?
p-value: p=<0.05
In kidney transplant patients, tacrolimus-based immunosuppression provides similar overall quality of life improvements to cyclosporine, but with significantly better scores in physical appearance.
Shield et al. (1997) conducted an RCT in Kidney transplant (n=303). Tacrolimus vs. Cyclosporine was evaluated on Health-related quality of life (HQL) scores (p=<0.05). Tacrolimus-based immunosuppression significantly improved health-related quality of life on the Bergner Physical Appearance scale compared to cyclosporine (P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: